Larotrectinib for treating NTRK fusion-positive solid tumours – guidance (TA630)

Larotrectinib is recommended for use within the Cancer Drugs Fund for NTRK fusion +ve solid tumours in adults and children only if the disease is locally advanced or metastatic or surgery could cause severe health problems and they have no satisfactory treatment options.


National Institute for Health and Care Excellence